Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
"nmCRPC prostate cancer guidelines" - Google News
Get the latest updates from "nmCRPC prostate cancer guidelines" - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated about 2 years ago
Nonmetastatic Castrationresistant Prostate Cancer NMCRPC Therapeutics Market With Complete SWOT Anal - PharmiWeb.com
about 2 years ago
Nonmetastatic Castrationresistant Prostate Cancer NMCRPC Therapeutics Market With Complete SWOT Anal PharmiWeb.com
Patient-Reported Outcomes and Changes in PSA in Patients With Advanced Prostate Cancer Treated With Apalutamide in the SPARTAN and TITAN Studies - OncLive
about 2 years ago
Patient-Reported Outcomes and Changes in PSA in Patients With Advanced Prostate Cancer...
Bayer Submits Application for NUBEQA to USFDA and EMA - Medical Dialogues
about 2 years ago
Bayer Submits Application for NUBEQA to USFDA and EMA Medical Dialogues
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B - Nasdaq
about 2 years ago
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B Nasdaq
Bayer Submits Applications in the US and EU for Additional Indication of NUBEQA® (darolutamide) - BioSpace
about 2 years ago
Bayer Submits Applications in the US and EU for Additional Indication of...
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide) - Valdosta Daily Times
about 2 years ago
Bayer Submits Applications in the U.S. and EU for Additional Indication of...
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide) - The Bakersfield Californian
about 2 years ago
Bayer Submits Applications in the U.S. and EU for Additional Indication of...
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide) - Business Wire
about 2 years ago
Bayer Submits Applications in the U.S. and EU for Additional Indication of...
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide) - Yahoo Finance
about 2 years ago
Bayer Submits Applications in the U.S. and EU for Additional Indication of...
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive pr - PharmiWeb.com
about 2 years ago
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in...
Part 1: Deciding Whether Next-Generation Scans Are Needed for nmCRPC - Targeted Oncology
about 2 years ago
Part 1: Deciding Whether Next-Generation Scans Are Needed for nmCRPC Targeted Oncology
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer | Small Molecules | News Channels - PipelineReview.com
about 2 years ago
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in...